HCPCS code J2180 – Meperidine and promethazine injection

Key takeaways

J2180 reports the premixed meperidine and promethazine HCl injection once sold as Mepergan, at one unit per 50 mg or less.

Medicare’s medically unlikely edit for J2180 is zero units in practitioner and outpatient hospital settings, because CMS lists the drug as discontinued.

When meperidine and promethazine come from separate vials, bill J2175 for meperidine and J2550 for promethazine, each with its own units and NDC.

Meperidine is a Schedule II opioid, so every dose needs a controlled-substance log entry alongside the administration record.

Claims software such as Pabau keeps the drug code, units and NDC tied to the treatment note before the claim goes out.

What is HCPCS code J2180?

HCPCS code J2180 is the Level II code for Injection, meperidine and promethazine HCl, up to 50 mg. It describes a premixed injection that combines meperidine, a Schedule II opioid analgesic, with promethazine, a phenothiazine antihistamine.

The combination was marketed as Mepergan and given by intramuscular injection. One billing unit covers up to 50 mg. The product is no longer manufactured, and Medicare now allows zero units of J2180 per day.

Official code descriptor and drug details

The J-series is maintained by the Centers for Medicare and Medicaid Services (CMS) HCPCS program. J2180 shares the J2000 range with J2175 for meperidine alone and J2550 for promethazine alone. That makes a code mix-up easy during claim entry.

Why Medicare pays nothing for J2180 today

J2180 is still a valid HCPCS code, but Medicare has no payable units for it. CMS sets its medically unlikely edit (MUE) at zero units per day.

The Medicare NCCI MUE tables effective October 1, 2026 list that zero in both the practitioner and the outpatient hospital files. The rationale recorded in both is “Drug discontinued.”

For comparison, the same October 2026 payment limit file sets J2175 at $9.652 per 100 mg and J2550 at $3.241 per 50 mg. Those rates change every quarter, so check the current CMS ASP pricing files before quoting them.

In practice, a J2180 line on a Medicare claim today usually signals a coding error. Either an old charge master entry still maps to it, or two separate drugs were keyed as the old combination.

How to bill meperidine and promethazine given together

When a patient receives meperidine and promethazine at the same visit, report each drug under its own code. Use J2175 for meperidine and J2550 for promethazine, then add the administration code.

HCPCS code J2175 is reported per 100 mg of meperidine. HCPCS code J2550 is reported per 50 mg or less of promethazine. Each line carries its own units and its own NDC. The diagram below maps both preparations to the lines they put on the claim.

Calculating billing units

Drug units are whole numbers on the claim. When a dose falls between two units, round up to the next whole unit and record the exact milligrams in the chart.

Medicare caps practitioner claims at 4 units per day for J2175 and 3 units for J2550. A dose above either edit needs documented medical necessity before the claim goes out.

A complete claim for these drugs carries six elements on the CMS-1500 or its electronic 837P equivalent:

1. The HCPCS code for each drug given, with its units: J2175, J2550, or J2180 for a premixed product
2. NDC number with qualifier N4, in 11-digit 5-4-2 format, for the vial actually used
3. Diagnosis code that supports medical necessity for each drug
4. Administration code, such as CPT 96372 for an intramuscular injection
5. Place-of-service code matching the setting where the drug was given, such as POS 11, 22 or 23
6. Rendering provider NPI and credentials in the billing and rendering provider fields

Using claims management software that ties NDC data to the dose record catches a wrong drug code before submission.

Documentation requirements for J2180

Meperidine is a DEA Schedule II controlled substance. The chart has to satisfy the billing record and the controlled-substance log at the same time.

Promethazine is not a controlled substance. Its injection carries an FDA boxed warning for severe tissue injury, so the route and injection site need recording too.

• Physician order: signed and dated, naming each drug, the dose in milligrams, the route and the clinical indication
• Administration record: milligrams of each drug given, route, injection site, date and time, and the administering clinician’s signature
• Diagnosis supporting medical necessity: the ICD-10-CM code on the claim links to an indication documented in the chart
• NDC and lot number: recorded for every vial used, in both the administration record and the controlled-substance log
• Schedule II log: a dispensing record for each meperidine vial, with any waste witnessed and signed per your state and facility policy
• Provider credentials: the prescriber holds a current DEA registration, and the administering clinician works within their licensure scope

Prior authorization requirements

Prior authorization (PA) rules for these drugs vary by payer and setting. Medicare Advantage plans, Medicaid programs and commercial payers can each set their own rules.

• Medicare fee-for-service: J2180 itself has no payable units, so PA questions apply to J2175 and J2550; check your MAC’s local coverage determination (LCD)
• Medicare Advantage: each plan sets its own PA policy, so verify before non-emergency use
• Medicaid: some states require PA for Schedule II opioids regardless of setting
• Commercial payers: many require PA for opioid injections outside the emergency department, so confirm during benefits verification

J2180 vs J2175, J2550, J3490 and other related codes

The code choice for this combination depends on how the drugs reached the syringe. A premixed product goes to J2180, and separate vials go to J2175 and J2550.

HCPCS code J3490 is a not otherwise classified (NOC) code for drugs without a specific HCPCS code. Meperidine and promethazine each have one, so billing either under J3490 invites a payer edit or a denial.

Common denial reasons for J2180 and how to avoid them

Most J2180 denials trace back to code selection rather than documentation. The denial management fix is to catch the code before submission instead of appealing afterward.

Appealing a denied J2180 claim

CMS gives J2180 MUE adjudication indicator 3, so a denial for exceeding the edit can be appealed. The claim adjustment reason code on the remittance names the edit that fired. Check it against these denial codes before you choose a route.

For a discontinued drug, the appeal rarely succeeds. When the wrong code caused the denial, ask your MAC whether a reopening or a corrected claim fits instead.

Where an appeal is justified, the Medicare process runs through these levels:

1. Redetermination: file within 120 days of the denial notice and attach the administration record, the controlled-substance log and the NDC documentation.
2. Reconsideration: file within 180 days of an unfavorable redetermination, when a Qualified Independent Contractor (QIC) reviews the claim.
3. ALJ hearing: request within 60 days of the QIC decision, if the amount in controversy meets the annual CMS threshold.

Review medical billing compliance requirements for your practice type when the same denial repeats across claims. A repeating pattern usually points to a charge master or workflow problem.

Compliance considerations when billing J2180

A Schedule II opioid on a claim draws closer scrutiny than most drug codes. A discontinued code on the same line adds a second reason for review.

• DEA registration: the prescriber must hold a current registration for Schedule II drugs, so track expiry dates 90 days ahead
• Controlled-substance log integrity: every meperidine vial needs a dispensing and waste record, and a missing entry invites audit findings
• Charge master review: retire or remap any J2180 entry so new charges flow to J2175 and J2550
• Quarterly claim review: compare each meperidine and promethazine claim against the log, the chart and the NDC records

How Pabau keeps drug codes and claims accurate

Most J2180 errors start at the charge master, where an old mapping sends a two-vial dose to a retired combination code. The mistake only surfaces weeks later as a denial.

In Pabau, the practice management platform we build, the drug, dose and NDC are recorded in the treatment note. The claim is built from that same record, so the code and units match what the clinician gave.

Billing staff can review drug lines before submission and track denials by reason code. Once the mapping is fixed, the same J2180 rejection stops coming back every month.

Bill injectable drugs under the right code

Pabau links each drug’s dose, NDC and billing units to the treatment record. Your team submits J-code claims that match what the clinician gave.

Book a demo

Conclusion

Treat J2180 as a code you should rarely need. With the premixed product discontinued and a Medicare MUE of zero, almost every combined dose belongs on J2175 and J2550.

The work that prevents these denials happens before the claim. Remap the charge master, record each vial’s NDC, and keep the controlled-substance log in step with the chart. Book a demo to see how Pabau ties drug codes, units and NDCs to the treatment record.

Continue your research

Need to understand how denials get resolved at scale? Denial management in healthcare covers the end-to-end workflow for tracking, categorizing, and appealing claim denials across your practice.

Want a compliance framework for your billing team? Medical billing compliance requirements outlines the audit controls and documentation standards practices need to stay clean during payer reviews.

Looking for a plain-language overview of how medical billing works? What is medical billing explains the full revenue cycle from charge capture through remittance posting.

Frequently asked questions